Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial
- Resource Type
- Abstract
- Source
- In
Blood 15 November 2022 140 Supplement 1:10947-10948 - Subject
- Language
- ISSN
- 0006-4971